Information Provided By: 
Fly News Breaks for February 10, 2017
ICPT
Feb 10, 2017 | 11:32 EDT
Cowen analyst Ritu Baral says that in a "pleasant surprise," Intercept Pharmaceuticals updated the primary analysis details of the Phase 3 NASH study interim look, which is expected to drive conditional approval. While enrollment has been slower than planned, Intercept negotiated updates with the FDA to allow for a 750 patient cohort, which, if anything, brings higher chances of trial success, Baral tells investors in a research note. The analyst has an Outperform rating on the shares with a $250 price target.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
